The activation of JNK, either by EGFR or chemotherapy agent, stabilizes BMI1 and MCL1 protein expressions through suppressing HUWE1 expression, which then promote tumour initiation and chemo‐resistance. This evidence concerns the gene MAPK8 and neoplasm.